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A B S T R A C T
Background: To describe the relationship between glycaemic
control, hyperglycaemic symptoms and quality of life
(HRQOL) in type 2 diabetic patients.
Methods: In a shared-care diabetes project HRQOL was
assessed. A total of 1664 patients with type 2 diabetes were
identified in 32 primary healthcare practices. Of these
patients, 1149 were included. HRQOL was measured
using a generic questionnaire (Rand-36), completed by
1006 of the 1149 participants.
Results: The number of hyperglycaemic symptoms was
higher in women (1.88) compared with men (1.64), without
differences in mean haemoglobin A1c (HbA1c) (7.5%).
Univariate analyses showed negative relationships between
all dimensions of the Rand-36 and hyperglycaemic
symptoms (p<0.001), but between only one dimension
and HbA1c (p=0.005). Multivariate analyses showed no
association between any of the dimensions of the Rand-36
and HbA1c, but the relationship between hyperglycaemic
symptoms persisted in all dimensions (p<0.001).
Notwithstanding these results, the presence of hyper-
glycaemic symptoms was related to higher HbA1c. 
Conclusion: In type 2 diabetic patients, as assessed by a
generic questionnaire, there is an evident relationship
between hyperglycaemic symptoms and HRQOL and not
between HbA1c and HRQOL. Subjective hyperglycaemic
symptoms are, independent of HbA1c, important for
HRQOL in type 2 diabetic patients, and should therefore
not be neglected in the management of diabetes.
K E Y W O R D S
Cross-sectional studies, diabetes mellitus type 2, hyper-
glycaemia, primary health care, quality of life 
I N T R O D U C T I O N
Over the past century, changes in human behaviour and
lifestyle have led to a dramatic increase in the prevalence
and incidence of diabetes mellitus type 2 worldwide. To
effect a significant reduction in the resulting premature
morbidity and mortality, an integrated approach to prevent
diabetes mellitus type 2 and its complications is called for.1
Targets in diabetic treatment are to improve glycaemic
symptoms and to reduce the risk of diabetes-related
complications and as such improve patients’ quality of
life (HRQOL). To achieve treatment goals, physicians and
patients must cooperate intensively; patients’ compliance
is essential. Patients can be expected to be more compliant
when their HRQOL improves as a consequence.
However, studies concerning the relationship between
HRQOL and glycaemic control prove confusing. In
patients with type 2 diabetes, an intensive regime to
improve glycaemic control seemed to have no effect on
the patient’s HRQOL.2 This was puzzling, since improved
glycaemic control usually leads to a decrease in hyper-
glycaemic symptoms, which again is expected to improve
HRQOL. The latter part is supported by Goddijn et al.3
who found, in a longitudinal study with a small number
of patients, that a reduction in hyperglycaemic symptoms
leads to an improved HRQOL.
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To optimise the treatment of diabetes mellitus, further
study into the manner in which diabetes-related symptoms,
glycaemic regulation and HRQOL are related is required.
This study describes the cross-sectional relationship between
glycaemic control, hyperglycaemic symptoms and
HRQOL in a large cohort of patients with type 2 diabetes.
M A T E R I A L S  A N D  M E T H O D S
Study population
In the region around Zwolle (the Netherlands), a large
shared-care diabetes project was initiated in 1998, the
Zwolle Outpatient Diabetes project Integrated Available
Care (ZODIAC).
In this project, general practitioners (GPs) are supported
by hospital-based diabetic specialist nurses (DSNs) in
their care of type 2 diabetic patients.
In part of the project, all subjects with type 2 diabetes
treated exclusively by their GPs in 32 practices are seen
annually by DSNs. In the first year of the project, 1664
subjects with type 2 diabetes mellitus were identified in
these practices. Patients treated by an internist (n=338)
were excluded. Fifty-seven patients were excluded by their
general practitioners because of a very short life expectancy
or expected insufficient cognitive abilities to fill in the
questionnaire. A total of 1269 patients were invited of
whom 1149 (90.5%) participated.
With the invitation to visit the DSN, the patients received
an HRQOL questionnaire (the Rand 36-Item Health Survey;
Rand-36),4 which they were requested to complete and
hand in together with a list of their current medication.
Their visit to the DSN included the following: (i) their
medical history was taken and added to the history provided
by the GP; (ii) height, weight and blood pressure were
measured; (iii) the feet were examined thoroughly (data
on the loss of sensibility were used in this study); and (iv)
after the visit, blood and urine were collected. A cross-
sectional analysis of the first-year data was made.
Measures
Medical history included year of onset diabetes, medication
(general and diabetic), smoking, coronary heart disease
and cerebrovascular disease. Coronary heart disease was
considered to be present when the patient had a confirmed
history of myocardial infarction, percutaneous transluminal
coronary angioplasty (PTCA) or coronary artery bypass
grafting (CABG). Cerebrovascular disease was considered
to be present when there was a confirmed history of
stroke or transient ischaemic attack (TIA). Neuropathy
was defined as the inability to feel the 5.07 Semmes
Weinstein monofilament at any one of three sites on each
foot, which is a reasonably sensitive and specific assessment
for diagnosing diabetic polyneuropathy.5 The BMI was
calculated from weight and length (kg/m2).
The major endpoint for metabolic control was the
haemoglobin A1c (HbA1c) level. Other laboratory measures
were serum creatinine, total cholesterol, high-density
lipoproteins (HDL), triglycerides, and albumin/creatinine
ratio in urine. Creatinine clearance was calculated using
the Cockcroft and Gault formula.6
The study group chose the Rand-36 to measure HRQOL
based on previous experiences with this questionnaire. It
is a reliable and valid generic measure, also in the Dutch
population.7,8 The Rand-36 contains nine health dimensions:
physical functioning, social functioning, role limitations
(physical), role limitations (emotional), mental health,
vitality, pain, general health perception and health change.
The nine dimensions were calculated in accordance with
the Rand-36 manual,4 except for ‘social functioning’ since
one of the two items was measured on a six- instead of a
five-point Likert scale. We used the formula as used by
Van der Zee et al.7 ((question 10j * 5 + question 6 * 6) 
- 11) * 100/49. To interpret the overall direction and
importance of the HRQOL effects,9 two summary measures
were calculated: the Physical Component Summary and
Mental Component Summary.3 The range of the scales is
from 0 to 100, a higher score meaning better HRQOL.
With the Rand-36, the patients received a list of glycaemic
symptoms and were asked to indicate whether they had
had any of six hyperglycaemic symptoms (fatigue, weight
loss without clear cause, itching, thirst, increased fluid
intake and increased urine production), or four hypogly-
caemic symptoms (excessive sweating, shaky sensation,
dizziness, and sudden appetite which disappeared when
food was taken) in the preceding month.
Analysis
Due to skewed distribution of the Rand-36 scales, non-
parametric statistics were used in the univariate analysis.
To compare continuous variables with dichotomic or
categorical variables, the Mann-Whitney test or Kruskal-
Wallis test was used, respectively. The Spearman rank
correlation was used to compare continuous variables. To
compare normally distributed variables with dichotomic
or continuous variables, (independent samples) the t-test
or Pearson correlation was used, respectively. Multivariate
analyses were performed using the parameter estimates
of the general linear model (GLM). The assumption of the
GLM that the distribution of the residual scores should
be normal was checked by inspecting the distribution of
the residuals using normal probability plots. The Rand-36
scores were used as dependent variables, the noncontinuous
measures as fixed variables and the continuous measures
Kleefstra, et al. Hyperglycaemia and quality of life.
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as covariates. The fixed or continuous variables were
included for analysis whenever there was at least one
significant univariate association with the Rand-36.
SPSS 10.0 for windows was used for data analysis.
R E S U L T S
General characteristics
In table 1 characteristics of the study population are
summarised. Women (n=662) represent the majority
(57.6%) of the study population. Mean age was 68.7
years, ranging from 21 to 97. Median diabetes duration
was 5.3 years. Insulin was used by 195 (17.0%) patients.
Mean HbA1c (7.5) was in the intermediate range (7 to 8.5)
according to the Dutch National Guidelines (upper limit
of normal 6.0%).10 No difference in HbA1c was found
between the sexes. The median number of hyperglycaemic
symptoms, known from 823 subjects, was 1 for both men
and women.
Determinants of quality of life
Univariate analysis
In the total study population of 1149 subjects, 1006
(87.6%) completed the Rand-36. No differences in HbA1c
were found between patients who completed the Rand-36
and those who did not. Univariate analysis was undertaken
for all measures. Table 2 shows the results of the Rand-36
in relation to HbA1c. One dimension (health change)
correlates significantly with HbA1c (r=-0.093, p=0.005).
Table 3 shows the results of the Rand-36 in relation to the
number of hyperglycaemic symptoms. For all scales the
correlation coefficients are at least -0.310 (p< 0.001), the
dimension ‘vitality’ having the strongest correlation 
(r=-0.546). 
All measures show at least one significant association
with the Rand-36, except for smoking, blood pressure and
cholesterol/HDL ratio (data not shown). When compared
with males, females showed lower scores on the Rand-36
(on eight scales). Patients with neuropathy showed lower
scores than patients without neuropathy (eight scales).
Increasing age was also related to lower scores (six scales).
An increase in the number of hypoglycaemic symptoms
was associated with lower scores on all Rand-36 scales,
with lower correlation coefficients (range (r)=-0.238 to
0.468) as compared with the number of hyperglycaemic
symptoms. Coronary heart disease and duration of dia-
betes both were related significantly to two scales.
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Table 1 Characteristics of study population 1998
(n=1149)
Male 487 (42.4)
Age (years) 68.7 ± 11.5 (21-97)
Diabetes duration (years)‡ 5.3 (2.5,10.4) (0-58)
Diabetes therapy
- Diet only 148 (12.9)
- Oral medication 806 (70.1)
- Insulin 169 (14.7)
- Insulin + oral medication 26 (2.3)
Metabolic regulation
- HbA1c (%) 7.5 ± 1.3 (4.8-13.1)
Macrovascular complications
- CHD 233 (20.3)
- Stroke/TIA 145 (12.6)
Microvascular complications
- Albuminuria* 460 (41.7)
- Neuropathy 333 (29.2)
Cockcroft (ml/min) 72.1 ± 28 (15-215)
Blood pressure (mmHg)
- Systolic 155 ± 25 (95-240)
- Diastolic 84 ± 11 (45-135)
Body mass index (kg/m2) 28.9 ± 4.8 (16-48)
Cholesterol/HDL 5.3 ± 1.6 (1.9-13.6)
Triglycerides (mmol/l) 2.6 ± 1.6 (0.5-15.2)
Smokers 207 (18.2)
No. hyperglycaemic 1 (0,3) (0-6)
symptoms (n=823)‡
No. hypoglycaemic 1 (0,2) (0-4)
symptoms (n=820)‡
Data are means ± SD (range) or n (% of known data). ‡Data are
median (P25,P75) (range). 
*Albuminuria ≥3 mg/mmol creatinine.
Table 2 Results RAND-36 divided for HbA1c
HbA1c category Good Inter- Poor Spearman
mediate correlation*
Range <7% 7-8.5% >8.5%
Total completed 441 473 239
questionnaires
Physical functioning 57.2 55.7 53.2 -.029
Social functioning 80.8 76.6 78.8 -.039
Role limitations 64.4 62.2 65.5 .024
(physical problem)
Role limitations 73.5 73.7 73.5 .021
(emotional problem)
Mental health 74.8 72.6 73.8 .003
Pain 71.7 69.7 70.7 -.009
Vitality 60.6 60.8 59.1 -.008
General health 61.9 61.5 60.6 -.006
perception
Health change 48.5 47.0 42.4 -.093‡
Physical component 66.7 64.9 65.3 -.014
summary
Mental component 70.6 69.6 70.0 .003
summary
*Spearman correlation was measured for continuous variable.
‡p=0.005.
Multivariate analysis
Table 4 shows the influence that each parameter had on the
different Rand-36 dimensions after correction for all other
included parameters by using the 95% confidence interval
and the proportion variance explained (eta squared). The
negative influence of the number of hyperglycaemic symp-
toms remained significant on all Rand-36 scales (all p<0.001).
Six other parameters also showed an independent significant
influence on some of the Rand-36 scales: increasing age (five
scales), BMI (four scales), coronary heart disease (five scales),
cerebrovascular disease (three scales), neuropathy (two scales)
and being female was negatively associated with seven scales.
In multivariate analyses, the remaining parameters lost
their influence on the Rand-36 scales (data not shown). 
When the number of hypoglycaemic symptoms is added
as a parameter to the multivariate analyses, it is significant
on all scales (data not shown), as is the number of hyper-
glycaemic symptoms. When the eta squared values of the
number of hypoglycaemic and hyperglycaemic symptoms
Kleefstra, et al. Hyperglycaemia and quality of life.
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Table 3 Results RAND-36 divided for number of
hyperglycaemic symptoms
Number of symptoms 0 1-2 3-6 Spearman
correlation
Total completed 211 368 237
questionnaires
Physical functioning 74.5 53.9 41.7 -.386‡
Social functioning 91.4 77.1 67.9 -.374‡
Role limitations 88.0 61.4 44.8 -.404‡
(physical problem)
Role limitations 91.5 72.3 58.7 -.328‡
(emotional problem)
Mental health 84.6 72.7 64.4 -.391‡
Pain 87.3 69.8 55.8 -.396‡
Vitality 79.2 58.7 45.6 -.546‡
General health perception 70.2 60.8 53.8 -.379‡
Health change 54.9 45.7 39.5 -.310‡
Physical component 82.2 64.3 52.3 -.500‡
summary
Mental component summary83.9 69.0 58.3 -.499‡
‡p<0.001.
Table 4 Clinical parameter estimates of Rand-36 dimensions
Physical Social Role Role Mental Pain Vitality General Health Physical Mental
functio- functio- limitations limitations health health change component component
ning ning (physical (emotional summary summary
problem) problem)
Age LB -1.14 -.45 -.92 -.74 -.09 -.33 -.20 -.07 -.34 -.46 -.27
UB -.79 -.12 -.38 -.22 .17 .03 .08 .14 -.09 -.19 -.00
eta .133‡ .014† .030‡ .018‡ .000 .003 .001 .001 .014† .030‡ .006*
BMI LB -1.63 -.82 -1.36 -.85 -.32 -0.99 -.49 -.34 -.46 -.85 -.46
UB -.84 -.08 -.12 .36 .30 -.16 .17 .14 .13 -.22 .15
eta .045‡ .007* .007* .001 .000 .009† .001 .001 .002 .015† .001
CDV LB 9.39 3.20 -.28 -.81 -3.99 -4.05 .73 -2.33 -.53 1.39 -.63
UB 21.18 14.49 18.70 17.67 5.09 8.25 10.45 4.84 8.18 10.90 8.47
eta .032‡ .012† .005 .004 .000 .001 .007* .001 .004 .009* .004
Neuro- LB 4.44 -2.44 -6.28 -3.58 -.97 .82 -2.47 -1.02 -.60 -.13 -.90
pathy UB 12.60 5.37 6.50 8.88 5.35 9.39 4.25 3.93 5.42 6.31 5.28
eta .021‡ .001 .000 .000 .002 .007* .000 .002 .003 .005 .003
CHD LB 6.48 -.70 -3.78 -7.29 -2.07 .08 .19 1.08 -3.45 1.28 -1.39
UB 16.06 8.52 11.41 7.52 5.40 10.16 8.13 6.89 3.65 8.98 6.02
eta .027‡ .004 .001 .000 .001 .005* .005* .009† .000 .009† .002
No. LB -8.13 -6.43 -11.99 -9.50 -5.62 -7.90 -8.74 -4.52 -4.39 -7.59 -6.76
hypergly- UB -5.81 -4.19 -8.37 -6.00 -3.82 -5.47 -6.82 -3.13 -2.67 -5.77 -5.03
caemic eta .152‡ .101‡ .142‡ .095‡ .123‡ ,130‡ .247‡ .129‡ .076‡ .223‡ .203‡
symptoms
Male/ LB 5.17 .79 1.44 4.26 3.11 4.34 .80 -1.86 -1.49 3.15 2.36
female UB 12.81 8.13 13.36 15.81 9.07 12.35 7.12 2.77 4.16 9.17 8.11
eta .027‡ .007* .008* .016† .021‡ .021‡ .008* .000 .001 .022‡ .018‡
*p<0.05, †p<0.01, ‡p<0.001. CDV = cerebrovascular disease; CHD = coronary heart disease. The first and second numbers represent the lower
(LB) and upper bound (UB) respectively of the 95% confidence interval of the regression coefficient (B). A negative number means the parame-
ter has a negative relationship with the Rand-36 dimension. The third number represents the partial eta squared (it describes the proportion of
total variability of the Rand-36 dimension attributable to a parameter).
are compared, the former scores higher on two scales:
mental health (eta squared 0.137 vs 0.051) and pain (eta
squared 0.085 vs 0.066).
Symptoms vs HbA1c
Table 5 shows the quintiles of HbA1c divided for the
number of hyperglycaemic and hypoglycaemic symptoms.
These data show that the number of hypoglycaemic
symptoms is not related to HbA1c, not even within the
lowest quintile. However, the number of hyperglycaemic
symptoms correlates significantly with HbA1c (p=0.033).
The average number of hyperglycaemic symptoms was
2.11 for patients in the highest quintile, and 1.62 to 1.71
for patients in the lower four quintiles. Table 6 shows the
mean HbA1c divided for presence or absence of separate
hyperglycaemic symptoms. HbA1c was significantly higher
in the group of persons with the presence of the symptoms
thirst (p=0.002) and increased fluid intake (p=0.011).
D I S C U S S I O N
This study shows a negative relationship between HRQOL
and glycaemic symptoms as well as a positive relationship
between hyperglycaemic symptoms and HbA1c. However,
no association between HRQOL and HbA1c was found.
Moreover, we found a negative association of HRQOL
with female gender, age, BMI, CHD, cerebrovascular
disease and neuropathy. Independent of each other, hypo-
glycaemic as well as hyperglycaemic symptoms have a
strong influence on HRQOL. The influence on HRQOL
by hyperglycaemic symptoms is stronger and associated
with HbA1c, whereas hypoglycaemic symptoms are not.
Goddijn et al.3 concluded in a longitudinal study with 94
patients that in type 2 diabetic patients reduction of
hyperglycaemic symptoms improved HRQOL. Earlier
studies using the Rand-36, SF-20 or SF-36 were unable to
find a relationship between HRQOL and HbA1c.
11-14 We
found only health change to be univariately and negatively
associated with HbA1c as did Johnson et al. in the Pima
Indians.15 This also applies to the longitudinal studies in
which the above-mentioned questionnaires were used.3,16
However, when other questionnaires were used, the asso-
ciation between HbA1c and HRQOL showed mixed
results, such as a significant negative association12,14,17,18
or no clear relation.2,14,19-22 The relation with glucose levels
was also unambiguous.23,24
The negative relationships between HRQOL and compli-
cations are what we expected:25,26 having a complication
relates to worse HRQOL. And although care providers
work hard to improve the risk profile for complications by
monitoring the HbA1c, blood pressure and lipid profile,
other (modifiable) factors should also be addressed. In
order to improve ‘quality of care’, some of the efforts
should also be directed to factors such as BMI and hyper-
glycaemic symptoms, since our results show that they
relate directly to HRQOL. At the moment a large part of
diabetes management is directed by objective measures
such as HbA1c, which are not directly related to HRQOL.
Hyperglycaemic symptoms receive far less attention. As
Hanestad et al.27 already postulated, this means that
important aspects of the patient’s life are neglected in
diabetes care.
The absence of a relationship between HRQOL and
HbA1c is hard to explain, especially when considering
the relationship between HRQOL and hyperglycaemic
symptoms and HbA1c and hyperglycaemic symptoms.
One would expect that if one of these three parameters is
high, it would relate positively to both other parameters.
It may be debatable whether the symptoms chosen (as
used by Goddijn et al.3) are truly hyperglycaemic.
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Table 5 Quintiles of HbA1c divided for number of
hyperglycaemic and hypoglycaemic symptoms
HbA1c Hyperglycaemic Hypoglycaemic 
symptoms (n)† symptoms (n)‡
4.8-6.4 (243) 1.71 ± 1.57 1.15 ± 1.17
6.5-7.0 (231) 1.71 ± 1.54 1.19 ± 1.13
7.1-7.6 (208) 1.71 ± 1.47 1.27 ± 1.18
7.7-8.5 (228) 1.62 ± 1.65 1.16 ± 1.13
8.6-13.1 (236) 2.11 ± 1.56 1.24 ± 1.17
†Correlation with HbA1c: 0.064 (p=0.033). Correlation was meas-
ured for continuous variable. ‡Correlation with HbA1c: 0.023
(p=0.261). Correlation was measured for continuous variable.
Table 6 HbA1c divided for each type of hyperglycaemic
symptom
Symptoms Yes No P
Fatigue 7.48 ± 1.2 (441) 7.50 ± 1.3 (348) .937
Weight loss 7.51 ± 1.3 (64) 7.27 ± 1.3 (717) .109
Itching 7.58 ± 1.3 (221) 7.44 ± 1.2 (561) .251
Thirst 7.73 ± 1.3 (196) 7.39 ± 1.2 (585) .002
Increased fluid 7.76 ± 1.5 (191) 7.39 ± 1.2 (595) .011
intake
Increased urine 7.55 ± 1.3 (332) 7.43 ± 1.2 (451) .243
production
Data are means ±SD (number of patients).
According to Van der Does et al.,22 fatigue is the dimension
most directly related to the present glycaemic status.
However, fatigue is a general and frequently occurring
symptom present in both patients with diabetes and with
depression. People with diabetes suffer more often from
depression compared with people without diabetes,28-30
and depression appears to be a good effect indicator of
HRQOL,31,32 in particular among female patients.30 The
presence of depression has not been assessed and may
have been of influence on our results.33 Except for the
symptom fatigue, the presence of all other hyperglycaemic
symptoms was associated with a higher HbA1c. Polyuria,
polydipsia and unexplained weight loss are classic symptoms
of diabetes mellitus.34 Moreover, most hyperglycaemic
symptoms were found in patients with the highest HbA1c,
supporting the fact that they are indeed hyperglycaemic
symptoms.
The limitations of our study are that the symptoms that
were chosen were not taken from a validated symptom
list, and that the number of missing values for the
hypoglycaemic and hyperglycaemic symptoms was quite
substantial. This may present an inaccurate representation
of the symptoms within the study population. For the
longitudinal follow-up of our population, validated symp-
tom score lists have been introduced. And although the
Rand-36 is closely related to the SF-36, the Rand-36 has
not been as extensively validated as the SF-36.35
Improving glycaemic control decreases the risk of 
complications. Whether it increases HRQOL directly will
have to be further studied longitudinally now that our
cross-sectional results suggest that this is not the case. As
such, physicians and DSNs have to be more aware of the
importance of motivating treatment adherence, as stated
earlier by Goddijn et al.3 If the association between hyper-
glycaemic symptoms and HRQOL in the absence of a
relation between HbA1c and HRQOL is confirmed in a
longitudinal design, caregivers will have to consider
these symptoms as a separate treatment objective. This
cross-sectional study of a large cohort is a basis for future
longitudinal analyses.
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